Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Mild COVID-19

COVID-19 Clinical Trial

Official title:

Open Multicenter Controlled Clinical Trial to Evaluate Safety and Efficacy of Aerosolized MIR 19 ® Inhalation in Adult Outpatients With Mild COVID-19.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05783206
• Other study ID #: 04-SiCoV/KK46-01/22
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: February 10, 2022
• Est. completion date: July 28, 2023

Study information

• Verified date: December 2023
• Source: National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the effectiveness and safety of MIR 19 ® in preventing development of moderate and/or severe course of the disease in mild COVID-19 outpatients.

Primary endpoint:

The proportion of patients with the development of moderate or severe COVID-19 disease (in accordance with the criteria specified in the Interim Guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)" by the Ministry of Health of the Russian Federation, version 14 of 27.12.2021 or current at the time of the study) by the 28th day of observation.

Description:

This is Phase 2b-3 multi-center controlled randomized study to assess the efficacy and safety of MIR 19 ® via 7 days treatment in a dose of 5.55 mg/day of participants with symptomatic mild COVID-19 who did not require hospitalisation.

The MIR 19® is a complex of siRNA, targeting Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) RNA-dependent RNA polymerase (RdRp) and peptide dendrimer (KK-46).

This study involved 2 cohorts who received:

1. 5.5 mg of the MIR 19 ® per day via inhalation route plus standard therapy which included symptomatic treatment, without any etiotropic drugs.

2. Standard therapy which included symptomatic treatment as well as etiotropic drugs except MIR 19 ®.

All subjects will undergo scheduled safety and efficacy assessments as outpatients to the end of the follow-up period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 984
• Est. completion date: July 28, 2023
• Est. primary completion date: July 28, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men and women over the age of 18 who have been diagnosed with COVID-19 and who need therapy on an outpatient basis according to the Interim Guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)"by Ministry of Health of the Russian Federation. Version 14 from 12/27/2021.

• Able to give informed consent and attend all study visits

• Duration of the disease from the first symptoms (presence of at least one of the following symptoms: fever, cough, myalgia, weakness, shortness of breath, headache, nausea, stool disorders, loss of appetite) up to the day of screening no more than 5 days.

• Negative pregnancy test for women with preserved reproductive potential

• Participants must agree to use the reliable contraception while on study medication and for posttrial contraception for 3 month

• The patient's ability to inhale the experimental drug

Exclusion Criteria:

• Respiratory rate is more than 22 / min

• Oxygen saturation - SpO2 = 94%.

• Decreased level of consciousness, agitation.

• Unstable hemodynamics (systolic blood pressure less than 100 mmHg or diastolic blood pressure less than 60 mmHg).

• Long-term systemic corticosteroid exposure.

• Autoimmune or inflammatory diseases (systemic / localized), as well as oncological diseases.

• Symptoms of moderate, severe or critical COVID-19 at the time of screening

• Positive blood tests for HIV, hepatitis B and ?, syphilis.

• Pregnancy and breast-feeding.

• Previous adverse reactions to the active substance and/or excipients included in the drug

• Chronic diseases of the cardiovascular system

• Type 1 diabetes.

• The following laboratory parameters are excluded: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, total and direct bilirubin >4 x upper limit of normal (ULN);

• C-reactive protein (CRP) level > 10 mg/L.

• Participation in other investigational drug or device clinical trials within 90 days prior to screening.

• History of alcohol, drug or chemical abuse

• Previous hospitalizations associated with the development of moderate and severe COVID-19.

• Mental illness.

• Receipt of plasma from a person who recovered from COVID-19 (convalescent plasma) up to 14 days before participating in the study, vaccination against SARS-CoV-2 less than 4 weeks before randomization.

• Any conditions that, according to the researcher's, may be a contraindication to the participation in the study.

Related Conditions & MeSH terms

• COVID-19

Intervention

Drug:
• MIR 19 ®
MIR 19 ® contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use. In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs.

Combination Product:
• Standard therapy
Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs (except MIR 19 ®)

Locations

Country	Name	City	State
Russian Federation	NRC Institute of Immunology FMBA	Moscow

Sponsors (1)

Lead Sponsor	Collaborator
National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Moderate or severe COVID-19	The proportion of patients with the development of moderate or severe COVID-19 disease (in accordance with the criteria specified in the Interim Guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)" by the Ministry of Health of the Russian Federation, version 14 of 27.12.2021 or current at the time of the study)	28th day of observation
Secondary	Etiotropic therapy	The proportion of patients required another etiotropic therapy COVID-19 during the study.	28th day of observation
Secondary	Severity of COVID-19 symptoms	Assessment of the severity of COVID-19 symptoms (nasal congestion, sore throat, shortness of breath, cough, weakness, myalgia, headache, chills, fever, nausea, vomiting, diarrhea, anosmia, ageusia) according to the patient's diary.	28th day of observation
Secondary	Results of polymerase chain reaction (PCR)	The proportion of patients with negative PCR to SARS-CoV-2 at visits 4, 5	28th day of observation
Secondary	Improvement / disappearance of COVID-19 symptoms	Time to clinical improvement / disappearance of symptoms according to the scale of assessment of the severity of symptoms of the disease	28th day of observation
Secondary	Duration of COVID-19 symptoms	Duration of clinical symptoms of COVID-19 disease (fever, cough, myalgia, weakness, shortness of breath, headache, nausea, stool disorders, loss of appetite, anosmia, ageusia) according to the patient's diary.	28th day of observation
Secondary	Moderate COVID-19	Proportion of patients with moderate COVID-19.	28th day of observation
Secondary	Severe COVID-19	Proportion of patients with severe COVID-19.	28th day of observation
Secondary	Critical COVID-19	Proportion of patients with critical COVID-19	28th day of observation
Secondary	Hospitalization	Proportion of hospitalized patients	28th day of observation
Secondary	Death rate	The proportion of deaths during the study	28th day of observation
Secondary	Worsening of COVID-19 symptoms	The proportion of patients with worsening of COVID-19 clinical symptoms during the study by at least 1 point	28th day of observation